Showing results (21-30 of 51) with videos related to
Sort By:
Pageof 6
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|August 6, 2019
NLG919/cyclodextrin complexation and anti-cancer therapeutic benefit as a potential immunotherapy in combination with paclitaxelJian Xu, Xiaohong Ren, Tao Guo, et al.Journal of Medicinal Chemistry|October 14, 2005
Development of nonsymmetrical 1,4-disubstituted anthraquinones that are potently active against cisplatin-resistant ovarian cancer cellsKlaus Pors, Jane A Plumb, Robert Brown, et al.Scientific Reports|August 6, 2016
The use of thermographic imaging to evaluate therapeutic response in human tumour xenograft modelsNosheen Hussain, David Connah, Hassan Ugail, et al.Molecular Cancer Therapeutics|July 29, 2003
Alchemix: a novel alkylating anthraquinone with potent activity against anthracycline- and cisplatin-resistant ovarian cancerKlaus Pors, Zennia Paniwnyk, Paul Teesdale-Spittle, et al.Journal of Medicinal Chemistry|November 28, 2006
Synthesis of DNA-directed pyrrolidinyl and piperidinyl confined alkylating chloroalkylaminoanthraquinones: potential for development of tumor-selective N-oxidesKlaus Pors, Steven D Shnyder, Paul H Teesdale-Spittle, et al.The Prostate|September 26, 2017
The unidirectional hypoxia-activated prodrug OCT1002 inhibits growth and vascular development in castrate-resistant prostate tumorsHeather Nesbitt, Jenny Worthington, Rachel J Errington, et al.Journal of Pharmacological and Toxicological Methods|February 5, 2011
An agarose spot chemotaxis assay for chemokine receptor antagonistsVictoria Vinader, Yousef Al-Saraireh, Helen L Wiggins, et al.Journal of Medicinal Chemistry|March 19, 2004
Synthesis and biological evaluation of novel chloroethylaminoanthraquinones with potent cytotoxic activity against cisplatin-resistant tumor cellsKlaus Pors, Zennia Paniwnyk, Ketan C Ruparelia, et al.Proteomics. Clinical Applications|May 11, 2017
Nipple aspirate fluid-A liquid biopsy for diagnosing breast healthSadr-Ul Shaheed, Catherine Tait, Kyriacos Kyriacou, et al.The Journal of Gene Medicine|February 16, 2005
A cytochrome P450 2B6 meditated gene therapy strategy to enhance the effects of radiation or cyclophosphamide when combined with the bioreductive drug AQ4NVerna McErlane, Anita Yakkundi, Helen O McCarthy, et al.Pageof 6